Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 13th, 2021

Updates in Heart Failure: From Definition to Treatments and Everything In-Between

Join top heart failure experts Drs Butler, Januzzi, and Bailey as they discuss the latest data on the use of SGLT2 inhibitors in patients with heart failure.


Screenshot 2021 11 02 132832

There have been multiple randomized clinical trials demonstrating benefits for patients with heart failure with reduced ejection fraction (HFrEF) and patients with heart failure with preserved ejection fraction (HFpEF) who received sodium-glucose cotransporter-2 (SGLT-2) inhibitors, including patients who did not have diabetes. The effects of these medications on hospitalizations for heart failure were consistent in independent trials and suggest that these agents also improve renal outcomes and reduce all-cause and cardiovascular death. In this live virtual meeting, our experts will help clinicians become familiar with the use of SGLT2 inhibitors, patient counseling, and risk mitigation in patients with heart failure.

Presenters:
Javed Butler, MD, MPH, MBA
Patrick H. Lehan Chair in Cardiovascular Research
Professor and Chairman
Department of Medicine
Professor of Physiology
University of Mississippi
Jackson, Mississippi

James L. Januzzi Jr, MD
Hutter Family Professor of Medicine
Harvard Medical School
Cardiology Division
Massachusetts General Hospital
Clinical Trials
Baim Institute for Clinical Research,   Boston, Massachusetts
Trustee
American College of Cardiology
Washington, DC

Alison L. Bailey, MD
Physician Director
Cardiovascular Disease at HCA Healthcare
Chattanooga, Tennessee


Sunday, November 14, 2021
5:00 PM – 6:30 PM EST
Register here

This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.

The American Heart Association (AHA) does not endorse any commercial products or programs. The links provided within this site are for convenience only, and are not an endorsement of either the linked-to entity, product or service.  AHA makes no warranties of any kind, express or implied, with regard to its third-party vendor websites.

Download
Interesting Stories
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
More Content
Screenshot 2021 11 02 130142
Sponsored Content
Antiplatelet Therapy in Patients With Coronary Artery Disease and Acute Ischemic Stroke/Transient Ischemic Attack
Oct 4th, 2022
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021